FFT Wealth Management LLC Has $347,000 Stake in Thermo Fisher Scientific Inc. (NYSE:TMO)

FFT Wealth Management LLC raised its stake in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) by 41.9% in the fourth quarter, according to the company in its most recent disclosure with the SEC. The firm owned 667 shares of the medical research company’s stock after acquiring an additional 197 shares during the quarter. FFT Wealth Management LLC’s holdings in Thermo Fisher Scientific were worth $347,000 as of its most recent filing with the SEC.

Several other institutional investors and hedge funds also recently made changes to their positions in the company. AMF Tjanstepension AB acquired a new position in shares of Thermo Fisher Scientific in the 3rd quarter worth approximately $42,409,000. Howard Capital Management Group LLC boosted its stake in Thermo Fisher Scientific by 0.5% in the third quarter. Howard Capital Management Group LLC now owns 54,575 shares of the medical research company’s stock worth $33,759,000 after purchasing an additional 286 shares in the last quarter. Arkadios Wealth Advisors grew its holdings in shares of Thermo Fisher Scientific by 2.1% during the third quarter. Arkadios Wealth Advisors now owns 1,273 shares of the medical research company’s stock worth $787,000 after purchasing an additional 26 shares during the last quarter. Autumn Glory Partners LLC raised its holdings in shares of Thermo Fisher Scientific by 107.1% in the third quarter. Autumn Glory Partners LLC now owns 1,367 shares of the medical research company’s stock valued at $846,000 after buying an additional 707 shares during the last quarter. Finally, Orrstown Financial Services Inc. lifted its position in Thermo Fisher Scientific by 251.0% during the 3rd quarter. Orrstown Financial Services Inc. now owns 1,811 shares of the medical research company’s stock worth $1,120,000 after buying an additional 1,295 shares in the last quarter. Institutional investors and hedge funds own 89.23% of the company’s stock.

Thermo Fisher Scientific Trading Up 0.8 %

NYSE TMO opened at $539.86 on Wednesday. The company has a debt-to-equity ratio of 0.59, a current ratio of 1.66 and a quick ratio of 1.29. Thermo Fisher Scientific Inc. has a one year low of $493.30 and a one year high of $627.88. The stock’s 50-day moving average is $548.80 and its 200-day moving average is $566.46. The firm has a market cap of $206.50 billion, a P/E ratio of 32.66, a P/E/G ratio of 2.99 and a beta of 0.77.

Thermo Fisher Scientific (NYSE:TMO) last released its earnings results on Thursday, January 30th. The medical research company reported $6.10 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $5.94 by $0.16. Thermo Fisher Scientific had a return on equity of 17.51% and a net margin of 14.78%. Sell-side analysts anticipate that Thermo Fisher Scientific Inc. will post 23.28 earnings per share for the current fiscal year.

Thermo Fisher Scientific declared that its Board of Directors has authorized a share buyback program on Friday, November 15th that permits the company to buyback $4.00 billion in outstanding shares. This buyback authorization permits the medical research company to repurchase up to 2% of its stock through open market purchases. Stock buyback programs are typically an indication that the company’s management believes its shares are undervalued.

Thermo Fisher Scientific Increases Dividend

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, April 15th. Stockholders of record on Friday, March 14th will be paid a dividend of $0.43 per share. This is a boost from Thermo Fisher Scientific’s previous quarterly dividend of $0.39. This represents a $1.72 annualized dividend and a dividend yield of 0.32%. The ex-dividend date of this dividend is Friday, March 14th. Thermo Fisher Scientific’s dividend payout ratio (DPR) is currently 10.41%.

Insider Activity

In other Thermo Fisher Scientific news, CEO Marc N. Casper sold 10,000 shares of Thermo Fisher Scientific stock in a transaction on Monday, December 2nd. The shares were sold at an average price of $530.26, for a total value of $5,302,600.00. Following the sale, the chief executive officer now directly owns 111,192 shares in the company, valued at approximately $58,960,669.92. The trade was a 8.25 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, CFO Stephen Williamson sold 9,825 shares of the firm’s stock in a transaction dated Tuesday, February 4th. The shares were sold at an average price of $585.59, for a total value of $5,753,421.75. Following the completion of the transaction, the chief financial officer now owns 27,296 shares of the company’s stock, valued at $15,984,264.64. The trade was a 26.47 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 20,125 shares of company stock worth $11,231,699 over the last ninety days. Insiders own 0.34% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities analysts have weighed in on TMO shares. Scotiabank boosted their target price on shares of Thermo Fisher Scientific from $605.00 to $650.00 and gave the stock a “sector perform” rating in a research note on Monday, February 3rd. Bank of America decreased their price objective on Thermo Fisher Scientific from $675.00 to $660.00 and set a “buy” rating on the stock in a research report on Friday, December 13th. Morgan Stanley boosted their target price on Thermo Fisher Scientific from $647.00 to $678.00 and gave the stock an “overweight” rating in a research report on Friday, January 31st. StockNews.com upgraded Thermo Fisher Scientific from a “hold” rating to a “buy” rating in a research report on Tuesday, January 14th. Finally, Citigroup upped their target price on shares of Thermo Fisher Scientific from $600.00 to $650.00 and gave the company a “neutral” rating in a research report on Friday, January 31st. Four research analysts have rated the stock with a hold rating and nineteen have issued a buy rating to the company’s stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $656.86.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.